Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TA + calcium carbonate is a research-stage multifunctional nanomedicine composed of tannic acid (TA) and calcium carbonate (CaCO3). It is typically synthesized via a biomineralization approach, often incorporating stabilizing polymers such as poly(ethylene glycol)-b-poly(glutamic acid) to form nanoparticles. The compound is designed to target the pathological microenvironment of inflammatory diseases, specifically addressing the elevated reactive oxygen species (ROS) levels and acidic conditions found in articular spaces. By neutralizing acidity and scavenging ROS, the nanomedicine reduces lipid peroxidation in M2 macrophages and decreases the production of pro-inflammatory factors. Research indicates potential therapeutic efficacy in treating rheumatoid arthritis and protecting chondrocytes from oxidative stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tannic acid + calcium carbonate.